The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

Specialty pharmaceutical company PharmaTher Holdings’ drug application for Ketamine has received a June 4 approval goal date, advancing approval of the drug in the U.S. PharmaTher said it is ...

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or ...

This follows the final approval from the US FDA for its abbreviated new drug application (ANDA). Shares of Lupin Ltd ended at ...

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Ketamine stock PharmaTher Holdings (CSE:PHRM) has received an amendment acknowledgement letter from the U.S. Food and Drug ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

PDS Biotechnology (NASDAQ:PDSB) said on Thursday it received U.S. FDA clearance for its Investigational New Drug application ...